1. Introduction

Prostate cancer accounts for 15% of all male tumors and is one of the most common malignant tumors of the male urinary system.[1] Recently, it has been reported that the incidence and mortality of prostate cancer have declined or stabilized.[2] To detect potential prostate cancer, imaging, assessment for tumor biomarkers, and prostate biopsy are commonly used in current hospital protocols. Transrectal ultrasound-guided systematic prostate biopsy is the gold standard to diagnose prostate cancer.[3] However, prostate biopsy is an invasive surgical procedure that can be associated with a number of postoperative complications, including infection and bleeding.

Remarkably, prostate cancer and cardio-cerebrovascular disease often occur together in the elderly.[4] Aspirin is a common anticoagulant that is widely used to prevent and treat cardio-cerebrovascular diseases in patients. Therefore, some patients might need to continue to take aspirin during prostate biopsy. Currently, the management of anticoagulants before prostate biopsy is controversial. In the clinic, aspirin is commonly stopped 7 to 10 days before prostate biopsy to reduce the incidence of bleeding complications.[5] However, some comparative studies have reported different conclusion. Two prospective studies reported that using low-dose aspirin during prostate biopsy did not increase the risk of bleeding.[6,7] In 2012, a meta-analysis reported that continuing to take aspirin during prostate biopsy could significantly increase the risk of hematuria,[8] but discontinuing aspirin before undergoing prostate biopsy might be unnecessary.

Meta-analysis is a useful statistical tool to overcome the limitation of different sample sizes used in individual studies and...
has the possibility of generating more accurate conclusions. Several related articles have been published since the 2012 meta-analysis was completed. Therefore, this study carried out an updated meta-analysis of all eligible published studies to assess the safety of transrectal ultrasound-guided prostate biopsy (TRUS-PB) in patients taking aspirin.

2. Methods

2.1. Search strategy

We searched the following databases for relevant literature from their inception to October 30, 2020: PubMed, EMBASE, Medline, Cochrane Central Register of Controlled Trials, Web of Science, Sinomed, Chinese National Knowledge Internet, and WANGFANG using the PRISMA guidelines. All studies that reported the outcomes of interest were included. Also, the reference from all relevant publications was examined. The English search term that were used included “Biopsy” OR “Biopsies” AND “Prostate” OR “Prostates” AND “Aspirin” OR “Acetylsalicylic Acid” OR “Acetylpyrin” OR “2-(Acetyloxy) benzoic Acid.”

2.2. Selection criteria

The following inclusion criteria were used:

1. The published article was written in English or Chinese.
2. The full text of the article was available.
3. The types of studies were randomized controlled trials (RCTs) or prospective studies.
4. All the patients included in the study underwent ultrasound-guided transrectal prostate biopsy. The patients in each study who continued to take aspirin or stopped taking aspirin during the biopsy were assigned to 1 of 2 groups, respectively.
5. Sufficient data were provided for the meta-analysis, including the total number of subjects and outcome indicators.

Several exclusion criteria were used, including

1. lacking the relevant and
2. the study did not involve the use of aspirin or TRUS-PB.

2.3. Quality assessment of the included studies

The quality of the studies’ methods was assessed using the Newcastle-Ottawa Scale (NOS) and the Review Manager version 5.2 software (https://community.cochrane.org/help/tools-and-software/revman-5). Three components are assessed with NOS, including selection (0–4 points), comparability (0–1 points), and outcome (0–3 points). A NOS scores of 6 or higher were used to indicate high-quality studies. Two reviewers independently performed this analysis. Any disagreements were resolved by consensus.

2.4. Data extraction

Two reviewers examined the studies included in this meta-analysis. They extracted the following data: first author, publication year, study period, country, follow-up, study design, total number of patients, number of patients on follow-up, the number of needle passes, the aspirin dose, and relevant outcome indicators. The included outcomes were hematuria, rectal bleeding, and hematospermia.

2.5. Statistical analysis

This meta-analysis was performed using Review Manager Software (Revman Manger version 5.2, Cochrane Collaboration, Oxford, UK). Pooled risk ratios (RRs) were calculated as the summary statistic for dichotomous variables. The RRs were reported with 95% confidence intervals (CIs). The Z test was used to determine the pooled effects of all included studies. Statistical significance was considered to exist when the P-value was less than .05. Statistical heterogeneity among studies was assessed using the Cochrane Chi-squared test and inconsistency (I²). The presence of heterogeneity was considered to be significant When P-value less than .05 or I² greater than 50%. A random-effects model was used to pool data when the results indicated the presence of significant heterogeneity. Otherwise, a fixed-effects model was used. Sensitivity analysis was performed to assess any significant heterogeneity and the stability of the results. Furthermore, a funnel plot was used to assess publication bias as the number of included studies was less than 10.

3. Results

3.1. Study identification

The search protocol and the results are shown in Figure 1. The initial literature search identified 526 potentially relevant studies. Two hundred fourteen studies were excluded due to duplication. Ultimately, 6 eligible studies with a total of 1047 patients taking aspirin and 2326 control patients, were included in this meta-analysis based on the defined selection criteria.

3.2. Characteristics and quality

Table 1 summarizes the baseline characteristics of the included studies. The 6 studies included 1 RCT and 5 prospective cohort studies (PCS). The methodological quality of these 6 studies was high, as indicated by a NOS score of 6 to 7 out of 9 points, and 5 PCS were considered to be high quality. The results are presented in Figures 2 and 3.

3.3. Meta-analysis results

3.3.1. Hematuria. All 6 studies reported complete data for hematuria, with 589 case of hematuria reported for patients in the aspirin group and 1204 cases in the non-aspirin group. Our assessment of hematuria in this meta-analysis showed no significant difference between the aspirin and non-aspirin groups (RR = 1.02, 95% CI [0.91–1.16], P = .71, Fig. 4). However, significant heterogeneity was observed among the studies (P = .02, I² = 61%).

3.3.2. Rectal bleeding. The 6 included studies reported complete data for rectal bleeding; 213 case of rectal bleeding were observed in the aspirin group, and 353 cases of rectal bleeding were reported in the non-aspirin group. Our assessment of rectal bleeding in this meta-analysis indicated that the risk for rectal bleeding in the aspirin group was significantly higher than the no aspirin group (RR = 1.27, 95% CI [1.09–1.49], P = .002, Fig. 5). The results for heterogeneity indicated no significant difference (P = .14, I² = 41%).

3.3.3. Hematospermia. The included studies reported complete data for hematospermia; 203 cases of hematospermia were observed in the aspirin group, and 501 hematospermia cases were included in non-aspirin group. Our meta-analysis of hemato-
# Table 1
Characteristics of the included studies.

| Study | Author            | Year | Period          | Country | Follow-up (d) | Study type | Total patients (n) | Patients on follow-up (n) | Needle passes (mg/d) |
|-------|-------------------|------|-----------------|---------|---------------|------------|-------------------|--------------------------|---------------------|
| 1     | Halliwell et al   | 2007 | NR              | UK      | 10–14         | PCS        | 1811              | 1740                     | NR                  |
| 2     | Chowdhury et al   | 2012 | 2009–2012       | UK      | 10–14         | PCS        | 930               | 902                      | 8/9/10              |
| 3     | Kanotis et al     | 2010 | 2007–2008       | Greece  | 10–14         | PCS        | 530               | 434                      | 12                  |
| 4     | Vasudeva et al    | 2015 | 2011–2014       | India   | 21            | PCS        | 783               | 681                      | 12                  |
| 5     | Maan et al        | 2003 | NR              | UK      | 7             | PCS        | 200               | 177                      | NR                  |
| 6     | Giannarini et al  | 2007 | 2005–2006       | Italy   | 14            | RCT        | 200               | 200                      | 10                  |

NR = not record, PCS = prospective cohort study, RCT = randomized controlled trial.

*From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).*

Figure 1. Flow diagram.
spermia revealed no significant difference between the aspirin and non-aspirin groups \( (RR = 0.93, 95\% CI [0.82–1.06], P = .29, \text{ Fig. 6}) \). No significant heterogeneity was observed in the fixed-effect model \( (P = .12, I^2 = 43\%) \).

3.4. Sensitivity analysis and assessment of publication bias

To test the stability of the results and assess the possible cause of heterogeneity, we performed a sensitivity analysis using an article-by-article culling method. When the research by Halliwell et al was excluded in the analysis of hematuria, the \( I^2 \) value changed from 85\% to 0\%, and the \( P \)-value changed from .02 to .57. Our results for hematuria continued to be stable, no matter which studies were removed from the analysis. Even though the pooled results for rectal bleeding did not exhibit any significant heterogeneity, the results were unstable. When the research by Halliwell et al was excluded, the result changed dramatically in that the \( P \)-value changed from .002 to .23. The results obtained for hematospermia were stable and did not exhibit significant heterogeneity in the analysis of sensitivity.

It has been noted that Begg’s test or Egger’s test exhibits relatively low power to assess publication bias when included the number of included studies is less than 10. Hence, we used a funnel plot to assess publication bias. As shown in Figure 7, the study by Mann et al was located on the outer edge of the funnel plot causing the funnel plot to be unbalanced and indicated a significant publication bias for rectal bleeding in the meta-analysis.

4. Discussion

In the present study, our meta-analysis investigated whether continuing to take aspirin would increase the risk of bleeding after TRUS-PB. We determined that aspirin increased the risk for rectal bleeding risk, but the risk of hematuria and hematospermia
did not differ from the control group. This study included 6 prospective studies, 1 RCT and 5 PCS, that enrolled 3373 patients. A follow-up report or questionnaire after the prostate biopsy was used to record each of the outcome indicators. All 6 studies reported that less than 20% of the patients were lost to follow-up. The sensitivity analysis indicated that the pooled results for hematuria and hematospermia were stable. Due to the reported statistically significant risk for rectal bleeding in most patients, the study by Hailliwell et al carried the highest weight in the pooled result for rectal bleeding. The results changed significantly after the study by Hailliwell et al was excluded. The remaining 5 studies reported that taking low-dose aspirin did not significantly increase the risk for rectal bleeding. Vasudeva et al performed a follow-up assessment 3 weeks after 12 core TRUS-PB. The result from that study indicated that compared with groups in which aspirin was not taken, taking low-dose aspirin

| Study or Subgroup | aspirin | non-aspirin | Risk Ratio | Risk Ratio |
|-------------------|---------|-------------|------------|------------|
|                    | Events  | Total       | Events     | Total      | M-H, Random, 95% CI | M-H, Random, 95% CI |
| Chowdhury et al 2012 | 73      | 216         | 228       | 617       | 15.8% | 0.91 [0.74, 1.13] |
| Giannarini et al 2007 | 33      | 65          | 31        | 65        | 8.7%  | 1.06 [0.75, 1.51] |
| Halliwell et al 2007 | 279     | 387         | 444       | 731       | 26.6% | 1.19 [0.91, 1.49] |
| Kariotis et al 2010 | 96      | 152         | 171       | 282       | 20.8% | 1.06 [0.91, 1.24] |
| Mann et al 2003   | 20      | 36          | 83        | 141       | 9.7%  | 0.94 [0.68, 1.30] |
| Vasudeva et al 2015 | 86      | 191         | 247       | 490       | 18.4% | 0.89 [0.75, 1.07] |
| Total (95% CI)    | 1047    | 2326        | 100.0%    | 0.91 [0.75, 1.16] |
| Total events      | 589     | 1204        | 0.01      | 100       |
| Heterogeneity: Tau² = 0.01; CHI² = 12.93, df = 5 (P = 0.02); I² = 61% |
| Test for overall effect: Z = 0.38 (P = 0.71) |

Figure 4. Forest plot of the hematuria of the aspirin group and the non-aspirin group.

| Study or Subgroup | aspirin | non-aspirin | Risk Ratio | Risk Ratio |
|-------------------|---------|-------------|------------|------------|
|                    | Events  | Total       | Events     | Total      | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Chowdhury et al 2012 | 31      | 216         | 71        | 617       | 16.6% | 1.25 [0.84, 1.85] |
| Giannarini et al 2007 | 20      | 65          | 18        | 65        | 8.1%  | 1.11 [0.65, 1.90] |
| Halliwell et al 2007 | 82      | 387         | 95        | 731       | 29.7% | 1.63 [1.25, 2.13] |
| Kariotis et al 2010 | 51      | 152         | 73        | 282       | 23.1% | 1.30 [0.96, 1.75] |
| Mann et al 2003   | 0       | 36          | 31        | 141       | 5.9%  | 0.06 [0.00, 0.97] |
| Vasudeva et al 2015 | 29      | 191         | 65        | 490       | 16.5% | 1.14 [0.76, 1.72] |
| Total (95% CI)    | 1047    | 2326        | 100.0%    | 1.27 [1.09, 1.49] |
| Total events      | 213     | 353         | 0.01      | 100       |
| Heterogeneity: CHI² = 8.41, df = 5 (P = 0.14); I² = 41% |
| Test for overall effect: Z = 3.06 (P = 0.002) |

Figure 5. Forest plot of the rectal bleeding of the aspirin group and the non-aspirin group.

| Study or Subgroup | aspirin | non-aspirin | Risk Ratio | Risk Ratio |
|-------------------|---------|-------------|------------|------------|
|                    | Events  | Total       | Events     | Total      | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Chowdhury et al 2012 | 26      | 216         | 85        | 617       | 13.6% | 0.87 [0.58, 1.21] |
| Giannarini et al 2007 | 22      | 65          | 23        | 65        | 7.1%  | 0.96 [0.60, 1.33] |
| Halliwell et al 2007 | 66      | 387         | 154       | 731       | 32.9% | 0.81 [0.62, 1.05] |
| Kariotis et al 2010 | 91      | 152         | 159       | 282       | 34.4% | 1.06 [0.90, 1.25] |
| Mann et al 2003   | 4       | 36          | 40        | 141       | 5.0%  | 0.39 [0.15, 1.02] |
| Vasudeva et al 2015 | 21      | 191         | 40        | 490       | 6.9%  | 1.35 [0.82, 2.22] |
| Total (95% CI)    | 1047    | 2326        | 100.0%    | 0.93 [0.82, 1.06] |
| Total events      | 230     | 501         | 0.01      | 100       |
| Heterogeneity: CHI² = 8.82, df = 5 (P = 0.12); I² = 43% |
| Test for overall effect: Z = 1.07 (P = 0.29) |

Figure 6. Forest plot of the hematospermia of the aspirin group and the non-aspirin group.
did not increase the risk of bleeding complications. Giannarini et al carried out an RCT and reported similar questionnaire. However, they did observe that the median duration for hematuria and rectal bleeding was significantly prolonged in patients taking low-dose aspirin. Hailliwell et al performed a PCS that included 1811 patients over 3.5 years. They reported that taking aspirin increased the risk and duration of hematuria and rectal bleeding after TRUS-PB, but the bleeding complication that did occur was minor and self-limiting. After reviewing all 6 studies, we found that the study by Hailliwell et al included more than 700 patients and it is possible that uncertain aspirin doses resulted in different baseline characteristics that could have been associated with high bleeding risk or heterogeneity in the study.

In 2012, Carmignani et al conducted a similar meta-analysis and determined that continuing to take aspirin while undergoing a TRUS-PB might increase the risk for hematuria but did not significantly affect the risk of rectal bleeding or hematospermia. Our updated meta-analysis included additional related studies and performed a sensitivity analysis to assess the stability and heterogeneity of the results. Although the result obtained for rectal bleeding was unstable, no significant heterogeneity was observed in the pooled rectal bleeding results. Therefore, our results for rectal bleeding and hematospermia were persuasive because of the low heterogeneity. Thus, it might be unnecessary to discontinue aspirin use to avoid an increased risk of bleeding when undergoing a TRUS-PB.

It has been reported that aspirin primarily inhibits cyclooxygenase-1 irreversibly and reduces the synthesis of thromboxane A2, which prevents platelet aggregation and thrombosis. Clopidogrel, ticlopidine, and cilostazol are other antiplatelet agents used to treat or prevention of cardiovascular diseases. Anticoagulant agents, such as warfarin, dabigatran, and rivaroxaban, act as vitamin K antagonists in clinical use. Although many antithrombotic agents have been used, studies investigating their effects on prostate biopsy have been limited, and their conclusions were inconsistent. In 2020, Lee et al reported a consensus statement concerning prostate biopsy from the Korean Society of Urogenital Radiology. They reported that most doctors stopped the administration of anticoagulants or antiplatelets 1 week before a prostate biopsy due to the possible risk of higher bleeding. Similarly, the Canadian Urologic Association has recommended that antiplatelet agents or anticoagulants should be stopped before a patient undergoing a TRUS-PB. However, our meta-analysis indicated that continued administration of aspirin increased the incidence of rectal bleeding, but the risk of hematuria and hematospermia was not significantly higher than the non-aspirin group. In addition to the 6 studies included in this meta-analysis that reported similar conclusions, Raheem et al carried out a study that compared anticoagulation/antiplatelet and control groups. They reported that the risk of rectal bleeding in the anticoagulation/antiplatelet and control group was 40% vs 39%, respectively, but the risk for hematuria was increased in the control group. Ihezue et al reported that the severity and risk of bleeding complications were no worse in the anticoagulation group than in the control group.

Concerning antiplatelet and anticoagulation management, transperineal ultrasound-guided prostate biopsy (TPUS-PB) appears to be similar to TRUS-PB. Saito et al performed a comparative study that included 598 patients who underwent a TPUS-PB. The results indicated that even though the medication group exhibited an increased bleeding risk, which was minor, it was not necessary to discontinue the use of anticoagulant or antiplatelet agents. Asano et al reported that the incidence of bleeding between group of patients who continued to use antithrombotic during TPUS-PB and a control group did not exhibit any significant differences. Numerous high-quality studies also have reported similar results as those seen in our meta-analysis. In 2017, study published in the EAU reported that although anticoagulant use was related to increased bleeding risks (OR: 1.28; 95%CI: 1.14–1.45; P < 0.001), the increase in overall complication risk was modest. Similarly, the International Consultation on Urological Disease/American Urological Association (ICUD/AUA) reported that prostate biopsy is a safe
procedure for patients taking low-dose aspirin,[22] which might increase the incidence of minor bleeding to approximately one-third higher than controls.

According to the Society of Interventional Radiology consensus guideline for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions, the TRUS-PB was a procedure with a moderate bleeding risk including hematuria (13–58.4%), rectal bleeding (2.3–21%), and hematospermia (5–28%).[15] Although these bleeding complications were reported to self-limiting, adverse events that could be associated with anticoagulant discontinuation must be considered. Biondi-Zoccai et al conducted a meta-analysis that included 50,279 patients at risk for coronary artery disease.[23] Their results indicated aspirin withdrawal was associated with a three-fold higher risk for major adverse cardiac events (OR = 3.14, 95% CI [1.75–5.61]). Similarly, Ferrari et al reported 1236 patients with acute coronary heart disease that 4.1% of the patients experienced the disease due to cessation of aspirin therapy.[24] Therefore, aspirin withdrawal is not always safer or necessary.

Our research exhibited several limitations: first, a follow-up assessment or questionnaire was used to collect the outcome data in 6 studies included in this meta-analysis. Patients might forget some details, which could lead to bias. However, it is difficult to avoid this type of bias due to this study design. Second, only 1 included study was a RCT. The addition of more high-quality RCTs would strengthen the conclusions. Third, the heterogeneity was high in the hematuria analysis. Although we observed the study generated heterogeneity, the underlying cause for heterogeneity was not clear. Finally, even though the pooled results for rectal bleeding did not exhibit significant heterogeneity, the sensitivity analysis indicated an unstable result. The inclusion of additional studies might increase the stability.

5. Conclusion

Our research indicated that taking aspirin did not increase the risk of hematuria and hematospermia after TRUS-PB. The risk of postoperative rectal bleeding did increase, but the bleeding was minimal and self-limiting. Therefore, we concluded that it is not necessary to stop taking aspirin before TRUS-PB. However, additional high-quality randomized controlled studies are needed to support this conclusion.

Acknowledgments

The authors would like to express their gratitude to EditSprings (https://www.editsprings.com/) for the expert linguistic services provided.

Author contributions

Di Chen: conceived the study, participated in its design, coordinated, and drafted the manuscript.
Gang Liu: article review, data extract, and manuscript revising;
Yurun Xie: data extract and performed the bias evaluation.
Changsheng Chen: data extract and performed the bias evaluation.
Zhihua Luo: manuscript revising. Yujun Liu: design, project development, supervisor, and manuscript revising. All authors read and approved the final manuscript.

Conceptualization: Yujun Liu.
Data curation: Yurun Xie, Zhihua Luo.

Investigation: Changsheng Chen.
Methodology: Di Chen.
Software: Changsheng Chen.
Supervision: Gang Liu.
Writing – original draft: Di Chen.
Writing – review & editing: Gang Liu.

References

[1] Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health 2018;12:1807–23.
[2] Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jamal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020;77:38–52.
[3] Borghesi M, Ahmed H, Nam R, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 2017;71:353–65.
[4] Leong DP, Frater V, Shayaneg B, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC Study. J Urol 2020;203:1109–16.
[5] El-Hakim A, Moussa S. CUA guidelines on prostate biopsy methodolo.
[6] Di Chen.
[7] Halliwell OT, Yadegefar GA, Lane C, Dewbury KC. Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications. Clin Radiol 2008;63:557–61.
[8] Giannarini G, Mogorovich V, Valen F, et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology 2007;70:501–5.
[9] Carmignani L, Picozzi S, Bozzini G, et al. Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis. Transl Apher Sci 2011;45:275–80.
[10] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
[11] Lee MS, Moon MH, Kim CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 2014; 14:45.
[12] Chowdhury R. Should warfarin or aspirin be stopped prior to prostate biopsy? An analysis of bleeding complications related to increasing sample number regimes. Clin Radiol 2012;67:64–70.
[13] Karioits I, Philippou P, Volanis D, Serafetinides E, Delakas D. Safety of ultrasound-guided transrectal extended prostate biopsy in patients receiving low-dose aspirin. Int Braz J Urol 2010;36:308–16.
[14] Vasudeva P, Kumar N, Kumar A, et al. Safety of 12 core transrectal ultrasound-guided prostate biopsy in patients on aspirin. Int Braz J Urol 2015;41:1096–100.
[15] Maaen Z, Cutting CW, Patel U. Morbidity of transrectal ultrasonogra.
[16] Akhlaik BA, Ittikhar R, Shaikh AA. Use of aspirin and statin as primary prevention for cardiovascular diseases. Pak J Med Sci 2016;32:1336–9.
[17] Iheue CU, Smart J, Dewbury KC, Mehta R, Burgess L. Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications. Clin Radiol 2005;60:459–63. discussion 457–458.
[18] Lee MS, Moon MH, Kim CK, Park SY, Choi MH, Jung SL. Guidelines for transrectal ultrasonography-guided prostate biopsy: Korean Society of Urogenital Radiology Consensus Statement for Patient Preparation, Standard Technique, and Biopsy-Related Pain Management. Korean J Radiol 2020;21:422–30.
[19] Raheem OA, Casey RG, Galvin DJ, et al. Discontinuation of anticoagulant or antiplatelet therapy for transrectal ultrasound-guided prostate biopsies: a single-center experience. Korean J Urol 2012;53: 234–9.
[20] Saito K, Washino S, Nakamura Y, et al. Transperineal ultrasound-guided prostate biopsy is safe even when patients are on combination antiplatelet and/or anticoagulation therapy. BMC Urol 2017;17:53.
[21] Asano T, Kobayashi S, Yano M, Otsuka Y, Kitahara S. Continued administration of antiplatelet agents during transperineal prostate biopsy. Int Braz J Urol 2015;41:116–23.
[22] Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 2014;192:1026–34.

[23] Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667–74.

[24] Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005;45:456–9.